Navigation Links
Inspiro Medical Ltd. Completes a Successful First Clinical Trial in Asthmatic Children

TEL AVIV, Israel, June 6, 2013 /PRNewswire/ --

Inspiro Medical, a portfolio company of The Trendlines Group, recently completed a successful clinical trial for InspiromaticTM, its innovative, breath-synchronized, active dry powder inhaler.

The study, completed in May 2013 at Schneider Medical Center aimed to objectively assess, in a randomized, crossover, double blind study, the efficacy and safety profiles of formoterol (bronchodilator) treatment via the Inspiromatic in asthmatic children, compared to its delivery via a competitive inhaler already on the market.

30 children with asthma, aged 8-18, were randomly allocated to treatment with formoterol via the Inspiromatic inhaler or a competitive device.

The study met both primary and secondary endpoints. The results demonstrated superior results for of the Inspiromatic in pulmonary delivery of the active drug. Lung function test (FEV1) demonstrated a statistically significant improvement following formoterol delivery via the Inspiromatic. Moreover, the Inspiromatic was highly rated by patients. Successful delivery of the API was achieved even with patients with poor inhalation technique and even in low-flow inhalation rate.  

"I'm very happy with the study results showing that the Inspiromatic achieved safety and efficacy," said Nimrod Kaufmann , CEO of Inspiro Medical. "This successful study will enable us to move to the next step in the company development and partner with pharmaceutical companies to develop drug-device combinations and also bring better therapy to patients with poor inhalation technique."  

Despite the numerous aerosol delivery devices currently on the market, Inspiro Medical believes that their device can significantly improve effectiveness in deposing the necessary medication. Inspiromatic takes into account drug particle/droplet size; design of the delivery device; and the patient's ability to use and understand the device.

Following this successful trial, Inspiro Medical will continue partnering with global pharmaceutical companies to jointly develop combination products.

Inspiro Medical will be opening investment round A in Q3/2013 to further develop its device and support partnering activities.

Nimrod Kaufmann will present Inspiro's proven technology at BioMed 2013 in Tel Aviv on June 10.

Company contact details:

Nimrod Kaufmann , CEO
Tel: +972-72-260-7051

Media relations:

Efrat Kaduri
Ofir Shpigel Media and Public Relations

SOURCE Inspiro Medical Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Standardized Regulations Crucial for Growth in Global Dimensional Metrology Market for Medical Devices
2. Chicago Crime Commission calls on Gov. Quinn to veto medical marijuana bill
3. More Than 100 Winning Medicare Bidders In Maryland Dont Have Proper Licenses To Provide Medical Equipment To Patients
4. Astute Medical, Inc. patrocinerà il simposio informativo presso il meeting sulla nefrologia in terapia intensiva
5. Astute Medical, Inc., veranstaltet Symposium aus anlaß des Critical Care Nephrology Kongress
6. Astute Medical, Inc. va accueillir un symposium éducatif lors dune réunion dédiée à la réanimation néphrologique
7. UBM Canon Celebrates the 30th Anniversary of MD&M East, the East Coasts Largest Medical OEM Event, and the 15th Anniversary of the Medical Design Excellence Awards, the MedTech Industrys Premier Awards Program
8. MAQUET Medical Systems USA Launches LED Concealed Lighting System For Labor, Delivery And Recovery Room
9. Cheetah Medical Announces New Management Team
10. seca Launches the seca mBCA 514 - medical Body Composition Analyzer
11. Kettering Medical Center Acquires Elektas Versa HD Radiotherapy System
Post Your Comments:
(Date:11/25/2015)... YORK , November 25, 2015 ... market of self-monitoring blood glucose devices was valued at ... grow with a CAGR of 5.7% during 2015 - ... geriatric population and increasing prevalence of diabetes. In addition, ... diabetes care is also contributing to the growth of ...
(Date:11/25/2015)... -- Developmental, commercial, and regulatory/legal strategies ... pharmaceutical products, says GBI Research . ... all play a key role in boosting the profitability ... . --> Developmental, commercial, and ... the profitability of pharmaceutical products, says GBI Research ...
(Date:11/25/2015)... Frankreich, November 25, 2015 ... dass sie eine Lizenz für das Patent über eine ... UCBL und ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... AAP8 ins Leben gerufenen und von Edelris gemeinsam mit ... als ein Behandlungsziel für HBV identifiziert, und es wurden ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... accessible for all, Water For Empowerment ™ attracts volunteers together who want ... water by empowering women as key stakeholders in the process. The non-profit launched ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 ... ... manufacturer, launched offering factory direct sauna parts and accessories. , Sauna accessories ... representative of the bather’s style and personality. From basic styles for the purist ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... OK (PRWEB) , ... November 25, 2015 , ... On ... International training center for the Narconon network, announced the release of a new cutting ... 1966 the Narconon organization has been working with drug- and alcohol-addicted individuals with the ...
Breaking Medicine News(10 mins):